Mesodissection Device Phase II

Information

  • Research Project
  • 8524438
  • ApplicationId
    8524438
  • Core Project Number
    R44GM100645
  • Full Project Number
    2R44GM100645-02
  • Serial Number
    100645
  • FOA Number
    PA-11-335
  • Sub Project Id
  • Project Start Date
    3/1/2012 - 13 years ago
  • Project End Date
    3/31/2014 - 11 years ago
  • Program Officer Name
    EDMONDS, CHARLES G.
  • Budget Start Date
    4/1/2013 - 12 years ago
  • Budget End Date
    3/31/2014 - 11 years ago
  • Fiscal Year
    2013
  • Support Year
    02
  • Suffix
  • Award Notice Date
    3/18/2013 - 12 years ago
Organizations

Mesodissection Device Phase II

DESCRIPTION (provided by applicant): Microscopic analysis of tissue mounted on glass slides is commonly used to study cancer, non-neoplastic entities such as heart disease and diabetes, and normal cell function. Researchers utilize micro and macro tissue dissection techniques in order to recover specific areas of these tissue sections from the slides for subsequent molecular analysis including real time PCR, microarrays, sequencing, and mass spectrometry. When the area to be dissected is relatively large (a few mm), manual macrodissection is adequate. If single cell resolution is required, Laser Microdissection (LMD) is often employed. Both of these methods have their short comings, particularly when an intermediate level of resolution is needed (100¿m to 1 mm). The Phase II project continues the goal to develop the MESO system, which is an affordable, easy to use, tissue milling and fragment recovery technology for slide mounted tissue sections. AvanSci Bio has met the Specific Aims of the Phase I grant by developing the manufacturing prototype and successfully completing the planned performance evaluation experiments. However, challenging improvements in accuracy, resolution, and sample preparation methods are necessary to expand the usability of the MESO system. In addition, significantly more testing and validation are necessary to ensure the system performs reliably and up to expectations and to encourage adoption. The two Specific Aims of this Phase II include: 1) optimization of sample prep and milling conditions, beta site testing including performance evaluation and validation, and novel application development; and 2) design refinement primarily to the stage precision and blade pressure control, and improved hardness of xScisor blade and more refined fluid control. This new technology and product is expected to further research and clinical diagnostics by greatly reducing the cost and therefore broadening availability of high performance microdissection. We have demonstrated feasibility for Phase II development and commercialization. Our Phase III goal will be to ultimately manufacture and distribute the MESO System, including instrumentation, software, and consumables to clinicians and researchers doing slide mounted tissue dissection.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    597513
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:597513\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AVANSCI BIO, LLC
  • Organization Department
  • Organization DUNS
    967095378
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    841191476
  • Organization District
    UNITED STATES